Skip to content

Enhanced laser parameters for Micropulse Transscleral Cyclophotocoagulation (MPCPC) in glaucoma patients: a randomized controlled trial for evaluation of clinical efficacy and cost-effectiveness

Enhanced laser parameters for Micropulse Transscleral Cyclophotocoagulation (MPCPC) in glaucoma patients: a randomized controlled trial for evaluation of clinical efficacy and cost-effectiveness

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109929
Enrollment
Unknown
Registered
2025-09-26
Start date
2025-10-01
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

Conventional group:using the conventional laser settings of 2500mw x 300s x 31.3% on cycle (total energy: 234.8J)
Enhanced group:using the enhanced laser settings of 2500mw x 400s x 31.3% on cycle (total energy: 313J).

Sponsors

Department of Ophthalmology and Visual Sciences (DOVS), The Chinese University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 2. Best corrected visual acuity (BCVA) >= 20/100 3. Intraocular pressure (IOP) > 21 and -6) Note: If both eyes fulfilled the criteria, the worse eye will be recruited

Exclusion criteria

Exclusion criteria: 1. Patients unwilling to undergo Micropulse Transscleral Cyclophotocoagulation (MPCPC) 2. Contraindicated to MPCPC e.g. scleral thinning 3. Mild Visual Field defect (MD 6 months ago) 7. Systemic or topical use of steroid within 3 months of study entry’ diabetic retinopathy/maculopathy and pregnancy (associated with decrease in IOP)

Design outcomes

Primary

MeasureTime frame
IOP reduction;Best-corrected visual acuity (BCVA) and laser complications in peri-operative period up to 2 years;

Secondary

MeasureTime frame
requirement of IOP-lowering drugs to maintain an IOP <= 18 mmHg;proportion of eyes requiring additional glaucoma procedures(s);proportion of eyes with glaucoma progression, during the 2-year follow-up period;

Countries

China

Contacts

Public ContactTHAM Chee Yung Clement

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong

clemtham@cuhk.edu.hk+852 3943 5802

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026